Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Cytogen's ProstaScint

This article was originally published in The Gray Sheet

Executive Summary

Cytogen's ProstaScint: C.R. Bard will copromote the prostate cancer diagnostic capromab pendetide under a 10-year agreement announced Aug. 1. The deal calls for Bard to market the monoclonal antibody imaging agent to office and hospital-based urologists. Cytogen will be responsible for the completion of clinical trials, regulatory activities related to the PLA, manufacturing, distribution and marketing to the medical imaging community. Both companies will market the monoclonal antibody-based product to managed care organizations. Cytogen has said it plans initially to restrict availability of the imaging agent to certified sites. On July 22, FDA's Medical Imaging Drugs Advisory Committee unanimously recommended ProstaScint for detection of metastatic prostate cancer in high-risk patients to aid surgical staging and to detect recurrence of prostatic carcinoma...

You may also be interested in...



UK Biotech Financing Holds Up Despite Woodford and Brexit

Neil Woodford’s fall from grace and Brexit dragged on an otherwise buoyant sector

Dr Reddy’s Focuses On India And China

Dr Reddy’s sees its Indian domestic market and China as hot prospects as it pursues its “transformation journey” in which it is reducing its dependence on the slowing US market.

Glenmark Sells Gynecology Unit

Glenmark has struck a deal with private equity firm True North for its gynecology business in India and Nepal.

UsernamePublicRestriction

Register

MT006459

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel